COMMUNIQUÉS West-GlobeNewswire

MIMEDX Announces Restructuring and Cost Reduction Initiative
16/04/2026
Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost [...]
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
16/04/2026
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
Achieve Life Sciences Announces Up to $354 Million Private Placement
16/04/2026
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, [...]
Helsinn appoints Giacomo Braglia to the Board of Directors
16/04/2026
Lugano, Switzerland – April 16 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, is pleased to announce the appointment of [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs
16/04/2026
New findings support hypothesis that current nanoparticle designed for pancreatic and liver cancers could also work for colorectal cancer Lehi, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of [...]
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up [...]
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros Lille, le 16 avril 2026 - Roquette, un leader mondial des ingrédients d'origine végétale et un fournisseur majeur d’ [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros
16/04/2026
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros Lille, 16 April, 2026 – Roquette, a global leader of plant-based ingredients and pharmaceutical excipients for the health and [...]
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
16/04/2026
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First ‑ in ‑ class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation CAMBRIDGE, [...]
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
16/04/2026
EUROBIO SCIENTIFIC SIGNE UN ACCORD DÉFINITIF EN VUE DE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION L'acquisition du portefeuille « Lab Products » de CareDx ouvre de nouvelles [...]
Greywolf Therapeutics appoints Edwin Moses as Chair
16/04/2026
OXFORD, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin [...]
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
16/04/2026
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA ® (recombinant, adsorbed) for active immunization [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
16/04/2026
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
16/04/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or [...]
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
16/04/2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth [...]

Pages